Table 1.
Demographics and clinical characteristics of Million Veteran Program cohort
| Characteristics | No APOL1 p.N264K Alleles | ≥1 APOL1 p.N264K Alleles | ||
|---|---|---|---|---|
|
APOL1 Low Risk |
APOL1 HR |
APOL1 Low Risk |
APOL1 HR |
|
| Characteristics | N=101,216 | N=15,022 | N=4672 | N=582 |
| Age, median (IQR), yr | 59.0 (51.0–66.0) | 59.0 (51.0–66.0) | 59.0 (51.0–66.0) | 60.0 (53.0–66.0) |
| Male, n (%) | 87,266 (86.2) | 12,922 (86.0) | 4059 (86.9) | 509 (87.5) |
| eGFR, ml/min per 1.73 m2, median (IQR) | 87.0 (71.4–103) | 84.5 (69.0–101) | 86.7 (71.6–102) | 88.5 (73.1–103) |
| BMI, median (IQR) | 29.7 (26.0–33.8) | 29.8 (26.2–34.1) | 29.5 (26.1–33.9) | 29.4 (25.8–33.4) |
| Clinical variables | ||||
| Diabetes, n (%) | 33,950 (33.5) | 5126 (34.1) | 1569 (33.6) | 197 (33.8) |
| Hypertension, n (%) | 67,652 (66.8) | 10,447 (69.5) | 3124 (66.9) | 403 (69.2) |
| Systolic BP, mm Hg, median (IQR) | 130 (120–139) | 130 (120–140) | 130 (120–139) | 131 (120–140) |
| Diastolic BP, mm Hg, median (IQR) | 79.0 (72.0–86.0) | 79.0 (72.0–86.0) | 79.0 (72.0–86.0) | 79.0 (72.0–86.0) |
| Medications | ||||
| Renin–angiotensin–aldosterone system inhibition | 40,480 (40.0) | 6201 (41.3) | 1877 (40.2) | 234 (40.2) |
| No. of antihypertensives | ||||
| 1 or 2, n (%) | 37,516 (37.1) | 5685 (37.8) | 1726 (36.9) | 216 (37.1) |
| 3 or more, n (%) | 28,256 (27.9) | 4421 (29.4) | 1307 (28.0) | 174 (29.9) |
| Kidney disease outcomes | ||||
| CKD, n (%) | 15,179 (15) | 2896 (19.3) | 685 (3.6) | 71 (12.2) |
| ESKD, n (%) | 2973 (2.94) | 1054 (7.02) | 136 (2.91) | 14 (2.41) |
| Outpatient dipstick proteinuria ≥2+, n (%) | 5340 (7.69) | 1117 (10.8) | 218 (6.81) | 26 (6.27) |
| Nephrotic syndrome, n (%) | 684 (0.68) | 191 (1.27) | 31 (0.66) | 4 (0.69) |
| FSGS, n (%) | 83 (0.08) | 53 (0.35) | 3 (0.06) | 1 (0.17) |
| ADPKD | 324 (0.32) | 81 (0.54) | 17 (0.36) | 2 (0.34) |
Apolipoprotein L1 low risk, carrying 0 or 1 total copy of the apolipoprotein L1 risk variants G1 or G2. apolipoprotein L1 high risk, carrying two apolipoprotein L1 risk variants, either two copies of the apolipoprotein L1 G1 risk mutation, two copies of the apolipoprotein L1 G2 risk mutation, or one copy of apolipoprotein L1 G1 and one copy of apolipoprotein L1 G2. APOL1, apolipoprotein L1; HR, high risk; IQR, interquartile range; BMI, body mass index; ADPKD, autosomal dominant polycystic kidney disease; CKD, stage 3/stage 4 CKD.